# OTOF Gene Therapy: From Breakthroughs to Roadmaps

**Authors:** Qiuju Wang, Tobias Moser, Christine Petit

PMC · DOI: 10.1002/mco2.70639 · MedComm · 2026-03-02

## Full-text entities

- **Genes:** SLC26A4 (solute carrier family 26 member 4) [NCBI Gene 5172] {aka DFNB4, EVA, PDS, TDH2B}, TMC1 (transmembrane channel like 1) [NCBI Gene 117531] {aka DFNA36, DFNB11, DFNB7}, GJB2 (gap junction protein beta 2) [NCBI Gene 2706] {aka BAPS, CX26, DFNA3, DFNA3A, DFNB1, DFNB1A}, OTOF (otoferlin) [NCBI Gene 9381] {aka AUNB1, DFNB6, DFNB9, FER1L2, NSRD9}
- **Diseases:** hereditary hearing loss (MESH:D009386), congenital deafness (MESH:D003638), auditory neuropathy (MESH:C538268), hearing loss (MESH:D034381), autosomal recessive nonsyndromic deafness form 9 (MESH:C563396), auditory synaptopathy (MESH:D006311)
- **Chemicals:** OTO (MESH:C032752), calcium (MESH:D002118)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** 1273C>T, 2T>C, 2377G>T, c.2215-1G>C, 4225A>T

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12954134/full.md

## References

5 references — full list in the complete paper: https://tomesphere.com/paper/PMC12954134/full.md

---
Source: https://tomesphere.com/paper/PMC12954134